No Data
No Data
Analyst Forecasts For Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Are Surging Higher
Sangamo Stock Climbs 12% Post-market on FDA Update for ST-503
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment
Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy
Express News | Sangamo Therapeutics Inc - to Initiate Phase 1/2 Study for St-503 in Mid-2025
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
No Data
No Data
Andy-Lai OP : Trash stocks
WillLaw : patience grass hopper
Andy-Lai OP WillLaw : 几时哦
WillLaw Andy-Lai OP : when?
Andy-Lai OP WillLaw : Yes.
View more comments...